Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain ; volume:18 ; number:1 ; day:30 ; month:1 ; year:2018 ; pages:1-10 ; date:12.2018
BMC cancer ; 18, Heft 1 (30.1.2018), 1-10, 12.2018
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Arriola, Edurne
- Beteiligte Personen und Organisationen
-
García Gómez, Ramón
Diz, Pilar
Majem, Margarita
Martínez Aguillo, Maite
Valdivia, Javier
Paredes, Alfredo
Sánchez-Torres, José Miguel
Peralta Muñoz, Sergio
Barneto, Isidoro
Gutierrez, Vanesa
Andrade Santiago, Jesús Manuel
Aparisi, Francisco
Isla, Dolores
Ponce, Santiago
Vicente Baz, David
Artal, Angel
Amador, Mariluz
Provencio, Mariano
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-4004-7
- URN
-
urn:nbn:de:1111-20180327566
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Arriola, Edurne
- García Gómez, Ramón
- Diz, Pilar
- Majem, Margarita
- Martínez Aguillo, Maite
- Valdivia, Javier
- Paredes, Alfredo
- Sánchez-Torres, José Miguel
- Peralta Muñoz, Sergio
- Barneto, Isidoro
- Gutierrez, Vanesa
- Andrade Santiago, Jesús Manuel
- Aparisi, Francisco
- Isla, Dolores
- Ponce, Santiago
- Vicente Baz, David
- Artal, Angel
- Amador, Mariluz
- Provencio, Mariano
- SpringerLink (Online service)
Ähnliche Objekte (12)
EGFR exon 20 insertion mutations in NSCLC
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review
Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management
Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
EGFR exon 20 insertion mutations in NSCLC
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review
Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management
Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
EGFR exon 20 insertion mutations in NSCLC
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations : Invited short review
Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management
Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients